Bayer Ag · XETR:BAYN

Bayer — 25th European Society of Retina Specialists (EURETINA) Congress 2025

10 slides from Bayer's conference presentation, Sep 4, 2025

  1. Slide 1: PULSAR Extension: Clinical Improvements Sustained Over 156 Weeks With Aflibercept 8 mg in nAMD

    Extension PULSAR Extension: Clinical Improvements Sustained Over 156 Weeks With Aflibercept 8 mg in Patients With Neovascular Age-Related Macular Degeneration Aude Ambresin,1 Tien Y. Wong,2,3 Paolo Lanzetta,4,5 Jean-François Korobelnik,6,7 Frank G. Holz,8 Taiji Sakamoto,9 Sobha Sivaprasad,10 Andrea

  2. Slide 2: Disclosures

    Disclosures nAMD Extension • Aude Ambresin: Consulting fees from Apellis, Bayer, Novartis, and Roche • TYW: Consulting fees from Aldropika Therapeutics, Bayer, Boehringer Ingelheim, Eden Ophthalmic, Genentech, Iveric Bio/Astellas Pharma, Novartis, Oxurion, Plano, Roche, Sanofi, Shanghai Henlius, and

  3. Slide 3: PULSAR Extension Design

    PULSAR Extension Design nAMD Extension PULSAR (BL–W96) PULSAR Extension (W96–W156) (Masked) (Open-label and optional)a 2q8 arm (n=336) 2q88mg arm (n=208) Aflibercept 2 mg every 8 weeks Patients originally assigned to 2q8 after 3 initial monthly injections switched to aflibercept 8 mg every 12 weeks

  4. Slide 4: Patient Disposition and Baseline Characteristics

    Patient Disposition and Baseline Characteristics nAMD PULSAR PULSAR Extension Extension Total 2q88mg 8mg Total Patients entering PULSAR study (FAS), n 1009 – – – Patients entering PULSAR Extension (eFAS), n (%) – 208 (61.9)a 417 (62.0)a 625 (61.9)a Completion rate at Week 96, % 85.9 – – – Completio

  5. Slide 5: Mean BCVA Through Week 156

    Mean BCVA Through Week 156a nAMD Extension PULSAR PULSAR Extension (2q8 vs 8mgb) (2q88mg vs 8mgb) 70 66.9 (ETDRS Letters) 65.1 Mean BCVA 65 66.9 60.6 Week 96–156 (60 weeks) 64.2 60 59.6 2q88mg: 4.9 8 mg: 3.9 55 0 12 24 36 48 60 72 84 96 108 120 132 144 156 Week Mean number of active BL–Week 48 Wee

  6. Slide 6: Mean CRT Through Week 156

    Mean CRT Through Week 156a nAMD Extension PULSAR PULSAR Extension (2q8 vs 8mgb) (2q88mg vs 8mgb) 500 418 Mean CRT (µm) 400 418 300 285 275 274 274 200 0 12 24 36 48 60 72 84 96 108 120 132 144 156 Week Note: At Week 156, the 2q8→8mg group (n=208) and 8mg group (n=417) reported LS mean (95% CI) chan

  7. Slide 7: Dosing Intervals Through Week 156

    Dosing Intervals Through Week 156 nAMD Extension Last Completed Dosing Interval 21% Last Assigned Dosing Interval Proportion of patients (%) 100 100 21% 14% 40% 13% 16% 37% 24% Proportion of Patients (%) Proportion of patients (%) 80 39% 32% 80 ≥Q20 ≥Q20b Q24 ≥Q16 ≥Q20 19% 19% 26% 42% Q20–Q22 16% 60

  8. Slide 8: Reduction in CNV Lesion Area Through Week 156

    Reduction in CNVa Lesion Area Through Week 156 nAMD Extension 8 PULSAR PULSAR Extension 6.3 (2q8 vs 8mgb) (2q88mg vs 8mgb) 6 Lesion Area (mm2) 6.1 4.2 Mean CNV 4 2.8 2.9 2.0 2 2.1 1.5 0 0 12 24 36 48 60 72 84 96 108 120 132 144 156 Week aeFAS (observed cases) based on fluorescein angiography/fundus

  9. Slide 9: Ocular and Non-Ocular Safety From Main Baseline Through Week 156

    Ocular and Non-Ocular Safety From Main Baseline Through Week 156 nAMD Extension 2q88mg 8q12 8mg Total N (eSAF) 208 417 625 Ocular TEAEs, n (%)a 130 (62.5) 251 (60.2) 381 (61.0) Ocular SAEs, n (%)a 7(3.4) 21 (5.0) 28 (4.5) Intraocular inflammation, n (%)a 5 (2.4) 8 (1.9) 13 (2.1) Non-ocular SAEs, n

  10. Slide 10: PULSAR Extension: Key Week 156 Results

    PULSAR Extension: Key Week 156 Results nAMD • In the PULSAR Extension, functional and anatomic improvements were sustained through Week 156 in the Extension 2q88mg and 8mg groups • Mean BCVA and CRT were comparable at Week 156 between the 2q88mg and 8mg groups – Patients in the 2q88mg group achie

Bayer — 25th European Society of Retina Specialists (EURETINA) Congress 2025 on 6ix